The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Biotech Trends Update: Jubilant’s R&D Success Continues Drive Toward Innovation in Asia

world_map_2002One of the biotech trends we’re following in 2010 is the increasing innovative activity in India and China.  Both are booming not only as low cost manufacturing centers but also as innovative hubs adding R&D expertise and specialized know-how.

This week, the Indian company Jubilant and Endo Pharmaceuticals announced that they are expanding thier partnership following early and rapid success by Jubliant’s team.  Jubilant has been developing pre-clinical candidates for Endo’s oncology pipeline.  As Endo’s R&D VP says, they are executing on a “strategy of building Endo’s pipeline using a virtual discovery approach” as a complement to their in-licensing strategy.

Jubilant has been running with these types of “virtual discovery” deals, including its collaboration with AstraZeneca that we noted at the time (even as AZ is shedding in-house capacity today), a successful partnership with Lilly and tie-ups with academic institutions including Duke University and UAB.

FierceBiotech reports that Biocon’s Kiran Mazumdar-Shaw predicts a $5 billion Indian biotech business in 2011 that will “double to $10 billion by 2015″ based on “opportunities in clinical trials, manufacturing and more.” 

The greater the contribution R&D makes to India’s growth, the better positioned the country (and the region) will be in the coming years to lead the global industry forward.

Bookmark and Share

About these ads

4 responses to “Biotech Trends Update: Jubilant’s R&D Success Continues Drive Toward Innovation in Asia

  1. Pingback: Biotech Trends Update — IP Constituencies: India’s Courts Nix Drug Patents while India Courts Innovation « The Cross-Border Biotech Blog

  2. Pingback: Biotech Trends Update — IP Constituencies: Indian Industry Lobbies to Keep IP Out of Free Trade Agreement with EU « The Cross-Border Biotech Blog

  3. Pingback: IP Constituencies: Indian Industry Lobbies to Keep IP Out of Free Trade Agreement with EU « The RIC Blog

  4. Pingback: IP Constituencies: Indian Industry Lobbies to Keep IP Out of Free Trade Agreement with EU | RIC Centre

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 126 other followers